4.8 Review

The promise and challenge of therapeutic genome editing

期刊

NATURE
卷 578, 期 7794, 页码 229-236

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41586-020-1978-5

关键词

-

资金

  1. Innovative Genomics Institute
  2. HHMI
  3. Paul Allen Frontiers Group
  4. Defense Advanced Research Projects Agency (DARPA) [HR0011-17-2-0043]
  5. William M. Keck Foundation
  6. Centers for Excellence in Genomic Science of the National Institutes of Health [RM1HG009490]
  7. Somatic Cell Genome Editing Program of the Common Fund of the National Institutes of Health [U01AI142817-02]
  8. National Science Foundation [1817593]
  9. Collaborative MS Research Center Award from the National Multiple Sclerosis Society
  10. Direct For Biological Sciences [1817593] Funding Source: National Science Foundation
  11. Div Of Molecular and Cellular Bioscience [1817593] Funding Source: National Science Foundation

向作者/读者索取更多资源

Genome editing, which involves the precise manipulation of cellular DNA sequences to alter cell fates and organism traits, has the potential to both improve our understanding of human genetics and cure genetic disease. Here I discuss the scientific, technical and ethical aspects of using CRISPR (clustered regularly interspaced short palindromic repeats) technology for therapeutic applications in humans, focusing on specific examples that highlight both opportunities and challenges. Genome editing is-or will soon be-in the clinic for several diseases, with more applications under development. The rapid pace of the field demands active efforts to ensure that this breakthrough technology is used responsibly to treat, cure and prevent genetic disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据